RenovoRx, Inc. RNXT 深 滬
已收盤 02-06 16:00:00 美东时间
0.99
+0.039
+4.11%
華盛通- 最 高1.02
- 今 開0.96
- 成交量 30.85万股
- 最 低 0.95
- 昨 收 0.9509
- 總市值 3628.34万
- 52周最高 1.45
- 市盈率 靜 --
- 換手率 0.84%
- 52周最低 0.7006
- 委 比 24.12%
- 總股本 3664.99万
- 歷史最高 16.74
- 量 比 1.30
- 振 幅 7.36%
- 歷史最低 0.5306
- 每 手 1
- 風險率 0.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多RenovoRx Appoints Mark Voll CFO, Effective Feb. 1
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is
02-05 21:39
RenovoRx To Present New Clinical Data At 2026 Society Of Interventional Oncology Annual Scientific Meeting On Feb. 6
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device,
02-04 21:31
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The global oncology sector is rocketing toward $668 billion in 2034[...
01-30 23:19
RenovoRx's Abstract Submission Accepted
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device,
01-28 21:36
RenovoRx To Present New Clinical Data Abstract From PK And Pharmacodynamic Sub‑Study Of Ongoing Phase III TIGeR‑PaC Clinical Trial At 2026 ASCO GI
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx's TAMP Therapy Platform as a Targeted Drug-Delivery ApproachData Shows a PK Profile that May
01-08 21:32
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of AZZ Inc (NYSE:AZZ) rose in pre-market trading after the company repor...
01-08 17:25
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
【答案】 RenovoRx, Inc. announced that its abstract regarding the TAMP™ Therapy Platform and RenovoCath® device has been accepted for presentation at the 2026 ASCO GI Symposium. The study compares intra-arterial gemcitabine delivery to standard intravenous chemotherapy for locally advanced pancreatic cancer, with findings supporting reduced systemic drug levels and potential for fewer side effects. The presentation will occur on January 9, 2026, in S...
2025-12-11 13:30
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
RenovoRx, Inc. announced that CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9, 2025. The presentation will cover commercial efforts, market traction of RenovoCath, clinical advancements, and updates on the Phase III TIGeR-PaC trial for pancreatic cancer treatment. The company reported year-to-date revenue of approximately $900,000 as of September 2025. A replay will be available...
2025-12-01 13:30
RenovoRx Enters Capital on Demand Sales Agreement
RenovoRx ( ($RNXT) ) has provided an update. On November 14, 2025, RenovoRx, In...
2025-11-15 06:29
RenovoRx Expands Reach with RenovoCath Approval
RenovoRx ( ($RNXT) ) has issued an announcement. RenovoRx reported its third-qu...
2025-11-14 05:54
